Fundraising Fox

Absci

NASDAQ: ABSI

Portland, US · Delaware corporation · 6 known investors

absci.com ↗

Absci uses AI and wet lab research in iterative cycles to design novel antibody therapeutics and biologics for drug discovery. The company develops candidates for diseases including androgenetic alopecia through integrated computational design and laboratory validation.

AI & Machine LearningBiotechDeep Techin /absci@abscibio

Founders & leadership

ZJ
Zach JonassonDirector
BL
Bryan LawlisDirector
PB
Phil BarishExecutive Officer
DG
Daniel GoldDirector
SM
Sean McClainExecutive Officer30 Under 30 2019

Investors · 6

Das & Co.New York
Oregon Venture FundPortland · $500K – $5M
Phoenix Venture PartnersSan Mateo · $100K – $3M
Tachyon VenturesLos Angeles
Tau VenturesPalo Alto · $500K
Casdin CapitalreportedNew Yorkvia Eli Casdin · board

Reported raises · per SEC filings

Form D private placements
▶$125MraisedMar 2021 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Andreas PihlDirector
  • Gustavo MahlerDirector
  • Karen McGinnisDirector
  • Ivana Magovcevic-LiebischDirector
  • V. Bryan LawlisDirector
  • Zach JonassonDirector
  • Gregory SchiffmanExecutive Officer
  • Sean McClainExecutive Officer, Director
  • Eli CasdinDirector
  • Amrit NagpalDirector
Offering amount
$125M
Amount sold
$125M
First sale
Mar 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$70MraisedMar 2021 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Lawrence McClureExecutive Officer
  • Zach JonassonDirector
  • Eli CasdinDirector
  • Andreas PihlDirector
  • Amrit NagpalDirector
  • Karen McGinnisDirector
  • Gustavo MahlerDirector
  • Ivana Magovcevic-LiebischDirector
  • V. Bryan LawlisDirector
  • Gregory SchiffmanExecutive Officer
  • Sean McClainExecutive Officer, Director
Offering amount
$70M
Amount sold
$70M
First sale
Oct 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.4MraisedDec 2019 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Sean McClainExecutive Officer, Director
  • Shelley KlassenExecutive Officer
  • Zach JonassonDirector
  • Bryan LawlisDirector
  • Daniel GoldDirector
  • Gustavo MahlerDirector
Offering amount
$15M
Amount sold
$10.4M
Minimum investment
$10K
Proceeds to insiders
$1M
First sale
Dec 2019
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b, 4a5
Full filing on SEC EDGAR ↗
▶$12MraisedJun 2018 · 31 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Phil BarishExecutive Officer, Director
  • Daniel GoldDirector
  • Gustavo MahlerDirector
  • Sean McClainExecutive Officer, Director
  • Bryan LawlissDirector
  • Zach Zach JonassonDirector
  • Shelley KlassenExecutive Officer
Offering amount
$15M
Amount sold
$12M
Proceeds to insiders
$500K
First sale
May 2018
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b, 4a5
Full filing on SEC EDGAR ↗
▶$3.7MraisedApr 2016 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Zach JonassonDirector
  • Bryan LawlisDirector
  • Phil BarishExecutive Officer
  • Daniel GoldDirector
  • Sean McClainExecutive Officer
Offering amount
$6M
Amount sold
$3.7M
Minimum investment
$10K
Proceeds to insiders
$325K
First sale
Apr 2016
Incorporated
Limited Liability Company, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news